Does Oral Pentoxifylline Administration Improve Hemoglobin in Hemodialysis Patients?
Ključne riječi
Sažetak
Opis
Fifty out of 57 hemodialysis anemic patients were finally included. They were assigned to two groups of equal numbers. Oral Pentoxifylline 400mg once daily was added to the treatment group which was compared to the control group over a six months period regarding hemoglobin, hematocrit, serum albumin and CRP.
Inclusion criteria: (Patients with ESRD on HD who have hemoglobin <11 g/dl, taking Erythropoietin alfa 4000 -12000 I.U/wk and having a urea reduction ratio >65%.). There were 57 patients who met the inclusion criteria out of 158 patients.
Exclusion criteria: Iron deficiency anemia with transferrin saturation <30%, intact PTH>300pg/ml, vitamin B12 or folate deficiency (evidenced by macrocytosis), history of intolerance to pentoxifylline or other xanthine derivatives, recent retinal or cerebral hemorrhage or active peptic ulcer disease, pregnancy or breastfeeding, presence of systemic hematological disease or known hemoglobinopathy, major surgery, infection, acute myocardial infarction, or malignancy within the last three months and patients who refused to participate in the study.
Datumi
| Posljednja provjera: | 10/31/2018 |
| Prvo podneseno: | 11/01/2018 |
| Predviđena prijava poslana: | 11/02/2018 |
| Prvo objavljeno: | 11/05/2018 |
| Posljednje ažuriranje poslano: | 11/05/2018 |
| Posljednje ažuriranje objavljeno: | 11/07/2018 |
| Stvarni datum početka studija: | 10/31/2017 |
| Procijenjeni datum primarnog završetka: | 05/02/2018 |
| Procijenjeni datum završetka studije: | 05/03/2018 |
Stanje ili bolest
Intervencija / liječenje
Drug: treatment group
Faza
Grupe ruku
| Ruka | Intervencija / liječenje |
|---|---|
| Experimental: treatment group Group I: 29 patients (25 completed the study) that received the study agent (400mg of oral pentoxifylline daily for 6 months.), besides the appropriate weight-based dose of ESA (60-150I.U/kg/wk). | Drug: treatment group a known drug of xanthine derivatives used in intermittent claudication |
| No Intervention: control group Group II: 28 patients (25 completed the study) who did not receive pentoxifylline but they received the appropriate dose of ESA. They were used as a control group and compared to group1 concerning the primary and the secondary outcomes. |
Kriterij prihvatljivosti
| Dobni uvjeti za studiranje | 18 Years Do 18 Years |
| Spolovi koji ispunjavaju uvjete za studij | All |
| Prihvaća zdrave volontere | Da |
| Kriteriji | Inclusion Criteria: - (Patients with ESRD on HD who have hemoglobin <11 g/dl, taking Erythropoietin alfa 4000 -12000 I.U/wk and having a urea reduction ratio >65%.). There were 57 patients who met the inclusion criteria out of 158 patients Exclusion Criteria: - Iron deficiency anemia with transferrin saturation <30%, intact PTH>300pg/ml, vitamin B12 or folate deficiency (evidenced by macrocytosis), history of intolerance to pentoxifylline or other xanthine derivatives, recent retinal or cerebral hemorrhage or active peptic ulcer disease, pregnancy or breastfeeding, presence of systemic hematological disease or known hemoglobinopathy, major surgery, infection, acute myocardial infarction, or malignancy within the last three months and patients who refused to participate in the study. |
Ishod
Primarne mjere ishoda
1. hemoglobin difference [after 6 months from the start]
Sekundarne mjere ishoda
1. difference in inflammatory markers [after 6 months from the start]
